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Problem Definition Aims For 
Improvement
Improve MRA 




• Identify barriers to prescription
• Improve prescription through combination of educational 
measures and EMR interventions
• Lectures and educational material
• “Smartphrases” in Epic for heart failure visits
• Possibility of expanding to other clinics and inpatient 
services
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MRA use in HFrEF is a 
Class 1A Recommendation1
RALES Trial: reduce mortality 
by 30% and lower 
hospitalizations by 35% in 
NYHA III – IV2
EMPHASIS-HF Trial: decrease 
cardiovascular death or HF 
hospitalization from 25.9% to 
18.3% in NYHA II3
• Patients at Jefferson 
Heart Institute between 





• NYHA class and other 
prescribed GDMT was 
recorded
67.5% 






• Greatly under-utilized 
• Recent increased interest in 
novel agents (ARNI and 
SGLT2 inhibitors)
• Continued focus needed on 
MRAs -> well-studied, 
effective, safe, and affordable 
